The text discusses the importance of molecular subtypes in precision medicine for colorectal cancer, the potential benefit of PIK3CA mutation in predicting response to nonsteroidal anti-inflammatory drug therapy, and the efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer.